CHUGAI PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT00345761
- Locations
- 🇯🇵
Hokkaido Region, Hokkaido, Japan
🇯🇵Kanto Region, Kanto, Japan
🇯🇵Kinki Region, Kinki, Japan
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
Phase 3
Completed
- Conditions
- Liver CirrhosisChronic Hepatitis C
- Interventions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 180
- Registration Number
- NCT00304551
- Locations
- 🇯🇵
Chugoku, Chugoku, Japan
🇯🇵Hokkaido Region, Hokkaido, Japan
🇯🇵Kanto Region, Kanto, Japan
Trial of Pegasys® in Patients With Chronic Hepatitis C
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 108
- Registration Number
- NCT00245414
- Locations
- 🇯🇵
Kyusyu Region, Fukuoka, Japan
🇯🇵Chugoku Region, Okayama, Japan
🇯🇵Kinki Region, Osaka, Japan
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 42
- Registration Number
- NCT00144586
A New Active Vitamin D, ED-71 for Osteoporosis
Phase 3
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1056
- Registration Number
- NCT00144456
Study of MRA in Patients With Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 135
- Registration Number
- NCT00144651
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 241
- Registration Number
- NCT00144547
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
Phase 3
Completed
- Conditions
- Chemotherapy Induced Anemia
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 122
- Registration Number
- NCT00144482
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 300
- Registration Number
- NCT00144469
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA (Tocilizumab)Other: current treatment
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 306
- Registration Number
- NCT00144508